Restricted accessResearch articleFirst published online 2024-04
Acceptability of Event-Driven and Long-Acting HIV Pre-Exposure Prophylaxis Formulations Among Transgender Women Engaged in Street-Based Sex Work in Baltimore,Maryland
We assessed acceptability of nonoral HIV pre-exposure prophylaxis (PrEP) formulations among transgender women (TW) engaged in street-based sex work in Baltimore, Maryland. In a K-means cluster analysis, TW (N=36) were partitioned into groups characterized by high interest in long-acting injectable PrEP only (Injectable Enthusiasts, 36%), high interest in injectables and subdermal implants (Long-Acting Acceptors, 36%), and low interest across PrEP formulations (Non-Acceptors, 28%). TW's interest in novel PrEP agents varied widely across formulations (range: 22–66%) and clustered around numerous relational, occupational, and structural factors, highlighting the importance of availing multiple PrEP formulations for this impacted population.
Get full access to this article
View all access options for this article.
References
1.
AVAC. PrEP watch: United States; 2021. Available from: https://www.prepwatch.org/country/united-states/ [Last accessed: July29, 2021].
2.
BecasenJS, DenardCL, MullinsMM, et al.Estimating the prevalence of HIV and sexual behaviors among the US transgender population: A systematic review and meta-analysis, 2006–2017. Am J Public Health, 2019; 109(1):e1–e8; doi: 10.2105/AJPH.2018.304727
3.
SongHJ, SquiresP, WilsonD, et al.Trends in HIV preexposure prophylaxis prescribing in the United States, 2012–2018. JAMA, 2020; 324(4):395–397; doi: 10.1001/jama.2020.7312
4.
PoteatT, WirtzA, MalikM, et al.A gap between willingness and uptake: Findings from mixed methods research on HIV prevention among Black and Latina transgender women. J Acquir Immune Defic Syndr, 2019; 82(2):131–140; doi: 10.1097/QAI.0000000000002112
5.
OgunbajoA, StorholmED, OberAJ, et al.Multilevel barriers to HIV PrEP uptake and adherence among Black and Hispanic/Latinx transgender women in southern California. AIDS Behav, 2021; 25(7):2301–2315; doi: 10.1007/s10461-021-03159-2
6.
WoodS, GrossR, SheaJA, et al.Barriers and facilitators of PrEP adherence for young men and transgender women of color. AIDS Behav, 2019; 23(10):2719–2729; doi: 10.1007/s10461-019-02502-y
7.
RaelCT, Lopez-RíosJ, McKennaSA, et al.Transgender women's barriers, facilitators, and preferences on tailored injection delivery strategies to administer long-acting injectable cabotegravir (CAB-LA) for HIV pre-exposure prophylaxis (PrEP). AIDS Behav, 2021; 25(12):4180–4192; doi: 10.1007/s10461-021-03357-y
8.
RaelCT, MartinezM, GiguereR, et al.Transgender women's concerns and preferences on potential future long-acting biomedical HIV prevention strategies: The case of injections and implanted medication delivery devices (IMDDs). AIDS Behav, 2020; 24(5):1452–1462; doi: 10.1007/s10461-019-02703-5
9.
GiguereR, FrascaT, DolezalC, et al.Acceptability of three novel HIV prevention methods among young male and transgender female sex workers in Puerto Rico. AIDS Behav, 2016; 20(10):2192–2202; doi: 10.1007/s10461-016-1387-9
10.
ShermanSG, ParkJN, GalaiN, et al.Drivers of HIV infection among cisgender and transgender female sex worker populations in Baltimore City: Results from the SAPPHIRE study. J Acquir Immune Defic Syndr, 2019; 80(5):513–521; doi: 10.1097/QAI.0000000000001959
11.
LiuC, HuT, GeY, et al.Which Distance Metric is Right: An Evolutionary K-Means View. In: Proceedings of the 2012 SIAM International Conference on Data Mining (SDM). Anaheim, CA: Society for Industrial and Applied Mathematics;, 2012; pp. 907–918; doi: 10.1137/1.9781611972825.78
12.
RosenJG, ParkJN, SchneiderKE, et al.Mapping interests in event-driven and long-acting pre-exposure prophylaxis formulations onto the HIV risk environment of street-based female sex workers: A latent class analysis. AIDS Behav, 2022; 26(6):1992–2002; doi: 10.1007/s10461-022-03613-9
13.
HarlingG, MuyaA, OrtbladKF, et al.HIV risk and pre-exposure prophylaxis interest among female bar workers in Dar es Salaam: Cross-sectional survey. BMJ Open, 2019; 9(3):e023272; doi: 10.1136/bmjopen-2018-023272
14.
ClementME, KofronR, LandovitzRJ. Long-acting injectable cabotegravir for the prevention of HIV infection. Curr Opin HIV AIDS, 2020; 15(1):19–26; doi: 10.1097/COH.0000000000000597
15.
BarretoD, ShannonK, TaylorC, et al.Food insecurity increases HIV risk among young sex workers in metro Vancouver, Canada. AIDS Behav, 2017; 21(3):734–744; doi: 10.1007/s10461-016-1558-8
16.
LogieCH, Lacombe-DuncanA, KennyKS, et al.Associations between police harassment and HIV vulnerabilities among men who have sex with men and transgender women in Jamaica. Health Hum Rights, 2017; 19(2):147–154.
17.
AbramovichA, de OliveiraC, KiranT, et al.Assessment of health conditions and health service use among transgender patients in Canada. JAMA Netw Open, 2020; 3(8):e2015036; doi: 10.1001/jamanetworkopen.2020.15036
18.
BielloKB, HosekS, DruckerMT, et al.Preferences for injectable PrEP among young U.S. cisgender men and transgender women and men who have sex with men. Arch Sex Behav, 2018; 47(7):2101–2107; doi: 10.1007/s10508-017-1049-7
19.
QuaifeM, EakleR, Cabrera EscobarMA, et al.Divergent preferences for HIV prevention: A discrete choice experiment for multipurpose HIV prevention products in South Africa. Med Decis Mak, 2018; 38(1):120–133; doi: 10.1177/0272989X17729376
20.
AndrzejewskiJ, DunvilleR, JohnsMM, et al.Medical gender affirmation and HIV and sexually transmitted disease prevention in transgender youth: Results from the survey of today's adolescent relationships and transitions, 2018. LGBT Health, 2021; 8(3):181–189; doi: 10.1089/lgbt.2020.0367
21.
RosenJG, MalikM, CooneyEE, et al.Antiretroviral treatment interruptions among Black and Latina transgender women living with HIV: Characterizing co-occurring, multilevel factors using the gender affirmation framework. AIDS Behav, 2019; 23(9):2588–2599; doi: 10.1007/s10461-019-02581-x
22.
SeveliusJM, PoteatT, LuhurWE, et al.HIV testing and PrEP use in a national probability sample of sexually active transgender people in the United States. J Acquir Immune Defic Syndr, 2020; 84(5):437–442; doi: 10.1097/QAI.0000000000002403
23.
GrantRM, PellegriniM, DefechereuxPA, et al.Sex hormone therapy and tenofovir diphosphate concentration in dried blood spots: Primary results of the interactions between antiretrovirals and transgender hormones study. Clin Infect Dis, 2021; 73(7):e2117–e2123; doi: 10.1093/cid/ciaa1160
24.
FonsecaJRS. Clustering in the field of social sciences: That is your choice. Int J Soc Res Methdol, 2013; 16(5):403–428; doi: 10.1080/13645579.2012.716973
25.
U.S. Food and Drug Administration (FDA). FDA Approves First Injectable Treatment for HIV Pre-Exposure Prevention. Silver Spring, MD, USA; 2021. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention [Last accessed: December30, 2021].
